Plain-English translation of NCT05738694 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether two medications—axitinib and toripalimab—given before surgery can help prevent kidney cancer from returning in patients at high risk of recurrence. Researchers believe this combination may shrink tumors and boost the body's immune system before surgery, leading to better outcomes than surgery alone.
Some kidney cancers are more likely to return after surgery, even when the tumor is removed. Early research suggests this medication combination works well in advanced kidney cancer, so doctors want to see if giving it before surgery—rather than after—can prevent recurrence and help patients live longer without cancer.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to one of two groups: one group receives the two medications for several weeks before having surgery to remove the kidney, while the other group goes straight to surgery. You will have regular visits for blood tests, imaging scans, and check-ups to monitor your health and how well the treatment is working. The study will track how long you remain cancer-free after treatment.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China